BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34:2980-2987. [PMID: 27354485 DOI: 10.1200/jco.2016.66.9929] [Cited by in Crossref: 316] [Cited by in F6Publishing: 356] [Article Influence: 45.1] [Reference Citation Analysis]
Number Citing Articles
1 Khadela A, Chavda VP, Postwala H, Ephraim R, Apostolopoulos V, Shah Y. Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer. Cancers (Basel) 2023;15. [PMID: 36672492 DOI: 10.3390/cancers15020543] [Reference Citation Analysis]
2 Li Y, Feng Y, Luo F, Peng G, Li Y. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas. Front Immunol 2022;13:1089792. [PMID: 36726969 DOI: 10.3389/fimmu.2022.1089792] [Reference Citation Analysis]
3 Turner DC, Wada R, Zhou H, Wang X, de Greef R, Valiathan C, Zhang L, Zhang N, Kuchimanchi M, Chen TT, Ballas M, Visser SAG. Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making. CPT Pharmacometrics Syst Pharmacol 2023. [PMID: 36642813 DOI: 10.1002/psp4.12917] [Reference Citation Analysis]
4 Volpe A, Blasberg R, Serganova I, Ponomarev V. Imaging the immune cell in immunotherapy. NK Cells in Cancer Immunotherapy: Successes and Challenges 2023. [DOI: 10.1016/b978-0-12-822620-9.00008-2] [Reference Citation Analysis]
5 Chen M, Xu Y, Zhao J, Liu X, Liu X, Zhang D, Shi Y, Zhang L, Zhong W, Wang M. Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients. Clin Lung Cancer 2022:S1525-7304(22)00291-1. [PMID: 36635116 DOI: 10.1016/j.cllc.2022.12.003] [Reference Citation Analysis]
6 Zheng M, Wang W, Bu Y, Liu J, Ma J, Wang R, Ren X, Lu Z, Li J, Cai J. Pan-Cancer Analysis of the Roles and Driving Forces of RAB42. Biomolecules 2022;13. [PMID: 36671428 DOI: 10.3390/biom13010043] [Reference Citation Analysis]
7 Wang H, Xu Y, Zuo F, Liu J, Yang J. Immune-based combination therapy for esophageal cancer. Front Immunol 2022;13:1020290. [PMID: 36591219 DOI: 10.3389/fimmu.2022.1020290] [Reference Citation Analysis]
8 Du Y, Chu Q, Lou Y, He Y, Hu H, Hu Q, Huang M. Editorial: Immunotherapy for NSCLC with oncogenic driver variants. Front Oncol 2022;12:1095947. [PMID: 36568249 DOI: 10.3389/fonc.2022.1095947] [Reference Citation Analysis]
9 Voronova V, Vislobokova A, Mutig K, Samsonov M, Peskov K, Sekacheva M, Materenchuk M, Bunyatyan N, Lebedeva S. Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. Front Oncol 2022;12:1035884. [PMID: 36544712 DOI: 10.3389/fonc.2022.1035884] [Reference Citation Analysis]
10 Sedano R, Cabrera D, Jiménez A, Ma C, Jairath V, Arrese M, Arab JP. Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. Am J Gastroenterol 2022;117:1917-32. [PMID: 36455219 DOI: 10.14309/ajg.0000000000001983] [Reference Citation Analysis]
11 Li S, Zhu S, Wei H, Zhu P, Jiao Y, Yi M, Gong J, Zheng K, Zhang L. The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC. Biomedicine & Pharmacotherapy 2022;156:113959. [DOI: 10.1016/j.biopha.2022.113959] [Reference Citation Analysis]
12 Abedi Kiasari B, Abbasi A, Ghasemi Darestani N, Adabi N, Moradian A, Yazdani Y, Sadat Hosseini G, Gholami N, Janati S. Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy. International Immunopharmacology 2022;113:109365. [DOI: 10.1016/j.intimp.2022.109365] [Reference Citation Analysis]
13 Li Y, Peng G, Qin C, Wang X, Li Y, Li Y. Positive regulators of T cell proliferation as biomarkers for predicting prognosis and characterizing the immune landscape in lung adenocarcinoma. Front Genet 2022;13:1003754. [PMID: 36506303 DOI: 10.3389/fgene.2022.1003754] [Reference Citation Analysis]
14 Koh YW, Han J, Haam S, Lee HW. Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.996634] [Reference Citation Analysis]
15 Wang Y, Wang B, Xiang L, Deng J, Xu B, He P, Pu W, Wang H, Fan Y, Chen H. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review. Front Immunol 2022;13:1016647. [DOI: 10.3389/fimmu.2022.1016647] [Reference Citation Analysis]
16 Zhou S, Ren F, Meng X. Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy. Front Immunol 2022;13:955944. [DOI: 10.3389/fimmu.2022.955944] [Reference Citation Analysis]
17 Gou M, Qian N, Zhang Y, Wei L, Fan Q, Wang Z, Dai G. Construction of a nomogram to predict the survival of metastatic gastric cancer patients that received immunotherapy. Front Immunol 2022;13:950868. [DOI: 10.3389/fimmu.2022.950868] [Reference Citation Analysis]
18 Zhang B, Zeng J, Zhang H, Zhu S, Wang H, He J, Yang L, Zhou N, Zu L, Xu X, Song Z, Xu S. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Front Immunol 2022;13:974581. [DOI: 10.3389/fimmu.2022.974581] [Reference Citation Analysis]
19 Shi C, Qin K, Lin A, Jiang A, Cheng Q, Liu Z, Zhang J, Luo P. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. J Exp Clin Cancer Res 2022;41:268. [DOI: 10.1186/s13046-022-02469-0] [Reference Citation Analysis]
20 Karami Fath M, Babakhaniyan K, Anjomrooz M, Jalalifar M, Alizadeh SD, Pourghasem Z, Abbasi Oshagh P, Azargoonjahromi A, Almasi F, Manzoor HZ, Khalesi B, Pourzardosht N, Khalili S, Payandeh Z. Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms. Vaccines (Basel) 2022;10:1448. [PMID: 36146527 DOI: 10.3390/vaccines10091448] [Reference Citation Analysis]
21 Mussafi O, Mei J, Mao W, Wan Y. Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer. Front Oncol 2022;12:948405. [DOI: 10.3389/fonc.2022.948405] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
22 Chen Q, Shang X, Liu N, Ma X, Han W, Wang X, Liu Y. Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors. Front Immunol 2022;13:931718. [DOI: 10.3389/fimmu.2022.931718] [Reference Citation Analysis]
23 Punekar SR, Shum E, Grello CM, Lau SC, Velcheti V. Immunotherapy in non-small cell lung cancer: Past, present, and future directions. Front Oncol 2022;12:877594. [DOI: 10.3389/fonc.2022.877594] [Reference Citation Analysis]
24 Liu T, Li Y, Sun J, Tian G, Shi Z. Gitogenin suppresses lung cancer progression by inducing apoptosis and autophagy initiation through the activation of AMPK signaling. Int Immunopharmacol 2022;111:108806. [PMID: 35914447 DOI: 10.1016/j.intimp.2022.108806] [Reference Citation Analysis]
25 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
26 Shi C, Wang Y, Xue J, Zhou X. Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects. Front Immunol 2022;13:940288. [DOI: 10.3389/fimmu.2022.940288] [Reference Citation Analysis]
27 Sowmya S, Pushpalatha C, Augustine D, Sibikar P, Bharkhavy K, Varghese EA. Preclinical and Commercial Trials of Cancer Diagnosis via Nano‐Imaging and Nanovaccinology. Nanovaccinology as Targeted Therapeutics 2022. [DOI: 10.1002/9781119858041.ch6] [Reference Citation Analysis]
28 Wang Y, Niu X, Cheng Y, Zhang Y, Xia L, Xia W, Lu S. Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients. Clin Exp Immunol 2022;208:316-22. [PMID: 35514075 DOI: 10.1093/cei/uxac045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Stokes WA, Behera M, Jiang R, Gutman DA, Huang Z, Burns A, Sebastian NT, Sukhatme V, Lowe MC, Ramalingam SS, Sukhatme VP, Moghanaki D. Impact of concomitant fibrates on immunotherapy outcomes for advanced non-small cell lung cancer. Cancer Med 2023;12:358-67. [PMID: 35607930 DOI: 10.1002/cam4.4847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Ortiz-Cuaran S, Swalduz A, Foy JP, Marteau S, Morel AP, Fauvet F, De Souza G, Michon L, Boussageon M, Gadot N, Godefroy M, Léon S, Tortereau A, Mourksi NE, Leonce C, Albaret MA, Dongre A, Vanbervliet B, Robert M, Tonon L, Pommier RM, Hofman V, Attignon V, Boyault S, Audoynaud C, Auclair J, Bouquet F, Wang Q, Ménétrier-Caux C, Pérol M, Caux C, Hofman P, Lantuejoul S, Puisieux A, Saintigny P. Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer. Eur J Cancer 2022;169:106-22. [PMID: 35550950 DOI: 10.1016/j.ejca.2022.03.038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Orlov SV, Baldin PL, Diuzeva NV, Krechetova AV, Mordovskiy AA, Moskovchenko AN, Musaeva NE, Romanchuk OV. Osimertinib and routine practice: the experience of the drug application in different clinical situations in case of metastatic non-small cell lung cancer with an EGFR mutation. Case report. J Mod Onco 2022;24:41-49. [DOI: 10.26442/18151434.2022.1.201491] [Reference Citation Analysis]
32 Karaboué A, Collon T, Pavese I, Bodiguel V, Cucherousset J, Zakine E, Innominato PF, Bouchahda M, Adam R, Lévi F. Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer. Cancers 2022;14:896. [DOI: 10.3390/cancers14040896] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
33 Baglivo S, Mandarano M, Bellezza G, Minotti V, Bonaiti A, Fischer MJ, Birocchi I, Roila F, Metelli N, Ludovini V, Metro G. Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature. Oncol Ther. [DOI: 10.1007/s40487-022-00183-7] [Reference Citation Analysis]
34 Wang J, Chen P, Su M, Zhong G, Zhang S, Gou D, Moloney GM. Integrative Modeling of Multiomics Data for Predicting Tumor Mutation Burden in Patients with Lung Cancer. BioMed Research International 2022;2022:1-14. [DOI: 10.1155/2022/2698190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Gou M, Qu T, Wang Z, Yan H, Si Y, Zhang Y, Dai G. Neutrophil-to-Lymphocyte Ratio (NLR) Predicts PD-1 Inhibitor Survival in Patients with Metastatic Gastric Cancer. J Immunol Res 2021;2021:2549295. [PMID: 34993252 DOI: 10.1155/2021/2549295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
36 Inoue T, Narukawa M. Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis. Cancer Control 2022;29:107327482211406. [DOI: 10.1177/10732748221140694] [Reference Citation Analysis]
37 Xu B, Cheng H, Li K, Lv Y, Zeng X, Liu T, Yu W, Guo W. Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study. J Cancer Res Clin Oncol 2022. [PMID: 34973080 DOI: 10.1007/s00432-021-03873-3] [Reference Citation Analysis]
38 O’donovan A, Baldini C, Battisti NML. Radiotherapy and Systemic Anti-Cancer Treatment in Older Adults with Cancer and Frailty. Frailty in Older Adults with Cancer 2022. [DOI: 10.1007/978-3-030-89162-6_14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Gessner C, Moreno-Jaime B, Passalacqua R, Li S, McGuire K, Kaul M, Paccaly A, Quek RGW, Gao B, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Gullo G, Rietschel P. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med 2022;28:2374-80. [PMID: 36008722 DOI: 10.1038/s41591-022-01977-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
40 Yang F, Wang JF, Wang Y, Liu B, Molina JR. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers (Basel) 2021;14:109. [PMID: 35008273 DOI: 10.3390/cancers14010109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
41 Wiest N, Majeed U, Seegobin K, Zhao Y, Lou Y, Manochakian R. Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer. Front Oncol 2021;11:751209. [PMID: 34868953 DOI: 10.3389/fonc.2021.751209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Grecea M, Soritau O, Dulf D, Ciuleanu TE, Zdrenghea M. Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. Onco Targets Ther 2021;14:5275-91. [PMID: 34848970 DOI: 10.2147/OTT.S283892] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Wang CC, Huang KT, Chang HC, Tseng CC, Lai CH, Lan J, Liu TT, Huang CC, Lin MC. Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue. Thorac Cancer 2021. [PMID: 34841687 DOI: 10.1111/1759-7714.14216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Aredo JV, Hellyer JA, Neal JW, Wakelee HA. Consolidation Durvalumab Should Not Be Administered to Patients With Stage III EGFR-Mutant NSCLC. J Thorac Oncol 2021;16:1994-8. [PMID: 34809803 DOI: 10.1016/j.jtho.2021.07.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
45 Kandalaft LE, Harari A. Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. Cancers (Basel) 2021;13:5819. [PMID: 34830973 DOI: 10.3390/cancers13225819] [Reference Citation Analysis]
46 Hondelink LM, Hüyük M, Postmus PE, Smit VTHBM, Blom S, von der Thüsen JH, Cohen D. Development and validation of a supervised deep learning algorithm for automated whole-slide programmed death-ligand 1 tumour proportion score assessment in non-small cell lung cancer. Histopathology 2021. [PMID: 34786761 DOI: 10.1111/his.14571] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
47 Cai L, Du X, Zhang C, Yu S, Liu L, Zhao J, Zhao Y, Zhang C, Wu J, Wang B, Chen Y, Su X, Yan X, Li W. Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy. Cancer Immunol Immunother 2021. [PMID: 34731284 DOI: 10.1007/s00262-021-03095-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Ma L, Diao B, Huang Z, Wang B, Yu J, Meng X. The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Commun (Lond) 2021. [PMID: 34699691 DOI: 10.1002/cac2.12229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
49 Zhu GL, Yang KB, Tang SQ, Peng L. Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis. Cancer Med 2021;10:8272-87. [PMID: 34668660 DOI: 10.1002/cam4.4347] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Xiong A, Nie W, Zhou Y, Li C, Gu K, Zhang D, Chen S, Wen F, Zhong H, Han B, Zhang X. Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients. Front Immunol 2021;12:708558. [PMID: 34630387 DOI: 10.3389/fimmu.2021.708558] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
51 Wang B, Guo H, Xu H, Yu H, Chen Y, Zhao G. Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer. Cells 2021;10:2620. [PMID: 34685600 DOI: 10.3390/cells10102620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
52 Chmielewska I, Dudzińska M, Szczyrek M, Świrska J, Wojas-Krawczyk K, Zwolak A. Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab? PLoS One 2021;16:e0257484. [PMID: 34587185 DOI: 10.1371/journal.pone.0257484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Zhao H, Ning J, Gu Y, Zhang X, Yu W, Chen T, Luo Q. Consecutive severe immune-related adverse events after PD-1 inhibitor induction and surgery in locally advanced non-small cell lung cancer: a case report. Transl Lung Cancer Res 2021;10:3682-8. [PMID: 34584866 DOI: 10.21037/tlcr-21-603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Liu Q, Zhao G, Zhang X, Jiang N, Zhao Z, Wang Y, Xu S, Zhu L, Lau WY, Dai G, Liu R. Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Langenbecks Arch Surg 2021. [PMID: 34518900 DOI: 10.1007/s00423-021-02321-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Wang L, Liu F, Li J, Ma L, Feng H, Liu Q, Cho WC, Chen H, Chen H, Guo H, Li Z, Howard SC, Li M, Shan B, Gu W, Ji J. From Anti-PD-1/PD-L1 to CTLA-4 and to MUC1-Is the Better Response to Treatment in Smokers of Cancer Patients Drug Specific? J Pers Med 2021;11:914. [PMID: 34575691 DOI: 10.3390/jpm11090914] [Reference Citation Analysis]
56 Shen CI, Chao HS, Shiao TH, Chiang CL, Huang HC, Luo YH, Chiu CH, Chen YM. Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer. Sci Rep 2021;11:16122. [PMID: 34373555 DOI: 10.1038/s41598-021-95628-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
57 Ho RLY, Ho IAW. Recent Advances in Glioma Therapy: Combining Vascular Normalization and Immune Checkpoint Blockade. Cancers (Basel) 2021;13:3686. [PMID: 34359588 DOI: 10.3390/cancers13153686] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
58 Zhaorigetu, Farrag IM, Belal A, Badawi MHA, Abdelhady AA, Galala FMAA, El-Sharkawy A, El-Dahshan AA, Mehany ABM. Antiproliferative, Apoptotic Effects and Suppression of Oxidative Stress of Quercetin against Induced Toxicity in Lung Cancer Cells of Rats: In vitro and In vivo Study. J Cancer 2021;12:5249-59. [PMID: 34335941 DOI: 10.7150/jca.52088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
59 Rossi A, Pilotto S, Carbognin L, Ferrara MG, Belluomini L, Daniele G, Bria E. Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer. JMP 2021;2:207-22. [DOI: 10.3390/jmp2030018] [Reference Citation Analysis]
60 Gou M, Zhang Y, Liu T, Qu T, Si H, Wang Z, Yan H, Qian N, Dai G. The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy. Front Oncol 2021;11:655716. [PMID: 34211839 DOI: 10.3389/fonc.2021.655716] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
61 Budczies J, Kirchner M, Kluck K, Kazdal D, Glade J, Allgäuer M, Kriegsmann M, Heußel CP, Herth FJ, Winter H, Meister M, Muley T, Goldmann T, Fröhling S, Wermke M, Waller CF, Tufman A, Reck M, Peters S, Schirmacher P, Thomas M, Christopoulos P, Stenzinger A. Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunol Immunother 2021. [PMID: 34125345 DOI: 10.1007/s00262-021-02981-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
62 Guaitoli G, Tiseo M, Di Maio M, Friboulet L, Facchinetti F. Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis. Transl Lung Cancer Res 2021;10:2890-916. [PMID: 34295687 DOI: 10.21037/tlcr-20-941] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
63 Zheng X, Wei H. Organ-Specific Immune-Related Adverse Events for PD-1 Antibodies in Lung Cancer Treatment. Front Oncol 2021;11:628243. [PMID: 34094910 DOI: 10.3389/fonc.2021.628243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Wang Y, Gu T, Tian X, Li W, Zhao R, Yang W, Gao Q, Li T, Shim JH, Zhang C, Liu K, Lee MH. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. Front Immunol 2021;12:654463. [PMID: 34054817 DOI: 10.3389/fimmu.2021.654463] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
65 Ouyang T, Cao Y, Kan X, Chen L, Ren Y, Sun T, Yan L, Xiong B, Liang B, Zheng C. Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. Front Oncol 2021;11:621639. [PMID: 34046338 DOI: 10.3389/fonc.2021.621639] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
66 Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Cochrane Database Syst Rev 2021;4:CD013257. [PMID: 33930176 DOI: 10.1002/14651858.CD013257.pub3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
67 Shneider OV, Kamilova TA, Golota AS, Sarana AM, Sсherbak SG. Biomarkers and Target Therapy for Lung Cancer. Physical and rehabilitation medicine, medical rehabilitation 2021;3:74-94. [DOI: 10.36425/rehab63268] [Reference Citation Analysis]
68 Spagnolo F, Boutros A, Cecchi F, Croce E, Tanda ET, Queirolo P. Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review. BMC Cancer 2021;21:425. [PMID: 33865350 DOI: 10.1186/s12885-021-08165-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
69 Javadrashid D, Baghbanzadeh A, Derakhshani A, Leone P, Silvestris N, Racanelli V, Solimando AG, Baradaran B. Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Biomedicines 2021;9:373. [PMID: 33918146 DOI: 10.3390/biomedicines9040373] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 10.5] [Reference Citation Analysis]
70 Nishino M, Hong F, Ricciuti B, Hatabu H, Awad MM. Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol 2021;5:PO. [PMID: 34250409 DOI: 10.1200/PO.20.00478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
71 Qu J, Mei Q, Liu L, Cheng T, Wang P, Chen L, Zhou J. The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer. Ther Adv Med Oncol 2021;13:1758835921992968. [PMID: 33643442 DOI: 10.1177/1758835921992968] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
72 Feng P, Li H, Pei J, Huang Y, Li G. Identification of a 14-Gene Prognostic Signature for Diffuse Large B Cell Lymphoma (DLBCL). Front Genet 2021;12:625414. [PMID: 33643388 DOI: 10.3389/fgene.2021.625414] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
73 Zhang H, Liu P, Zhang Y, Han L, Hu Z, Cai Z, Cai J. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer. FEBS Open Bio 2021;11:911-20. [PMID: 33455075 DOI: 10.1002/2211-5463.13088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
74 Kumar S, Singh SK, Rana B, Rana A. Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights. Drug Discov Today 2021;26:951-67. [PMID: 33450394 DOI: 10.1016/j.drudis.2021.01.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
75 Myers JW, Peoples GE, Clifton GT. Overcoming Cancer Tolerance with Immune Checkpoint Blockade. Cancer Immunology 2021. [DOI: 10.1007/978-3-030-50287-4_6] [Reference Citation Analysis]
76 Goto H, Sugita K, Yamamoto O. Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease. Indian J Dermatol 2021;66:169-73. [PMID: 34188273 DOI: 10.4103/ijd.IJD_341_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Bajpai M, (David) Zhou Z. Biomarkers of Esophageal Cancers and Precancerous Lesions. Physiology in Health and Disease 2021. [DOI: 10.1007/978-3-030-67951-4_5] [Reference Citation Analysis]
78 Wu L, Ke L, Zhang Z, Yu J, Meng X. Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors. Front Oncol 2020;10:602762. [PMID: 33392095 DOI: 10.3389/fonc.2020.602762] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 6.7] [Reference Citation Analysis]
79 Ferrara R, Imbimbo M, Malouf R, Paget-Bailly S, Calais F, Marchal C, Westeel V. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Cochrane Database Syst Rev 2020;12:CD013257. [PMID: 33316104 DOI: 10.1002/14651858.CD013257.pub2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
80 Zhang Z, Zhang F, Yuan F, Li Y, Ma J, Ou Q, Liu Z, Yang B, Wang L, Tao H, Zhang S, Li X, Zhi X, Ge X, Bao H, Wu X, Hu Y, Wang J. Pretreatment hemoglobin level as a predictor to evaluate the efficacy of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Ther Adv Med Oncol 2020;12:1758835920970049. [PMID: 33224276 DOI: 10.1177/1758835920970049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
81 Yang S, Zhang W, Chen Q, Guo Q. Clinical Investigation of the Efficacy and Safety of Anlotinib with Immunotherapy in Advanced Non-Small Cell Lung Cancer as Third-Line Therapy: A Retrospective Study. Cancer Manag Res 2020;12:10333-40. [PMID: 33116888 DOI: 10.2147/CMAR.S280096] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
82 Bishay K, Tandon P, Bourassa-Blanchette S, Laurie SA, McCurdy JD. The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Curr Oncol. 2020;27:e486-e494. [PMID: 33173388 DOI: 10.3747/co.27.6251] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
83 Su C, Wang H, Liu Y, Guo Q, Zhang L, Li J, Zhou W, Yan Y, Zhou X, Zhang J. Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer. Front Oncol 2020;10:554313. [PMID: 33072580 DOI: 10.3389/fonc.2020.554313] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
84 Verschraegen CF, Jerusalem G, McClay EF, Iannotti N, Redfern CH, Bennouna J, Chen FL, Kelly K, Mehnert J, Morris JC, Taylor M, Spigel D, Wang D, Grote HJ, Zhou D, Munshi N, Bajars M, Gulley JL. Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study. J Immunother Cancer 2020;8:e001064. [PMID: 32907924 DOI: 10.1136/jitc-2020-001064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
85 Dudzińska M, Szczyrek M, Wojas-Krawczyk K, Świrska J, Chmielewska I, Zwolak A. Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients-Literature Review. Cancers (Basel) 2020;12:E2314. [PMID: 32824462 DOI: 10.3390/cancers12082314] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
86 Liang J, Li M, Sui Q, Hu Z, Bian Y, Huang Y, Zhan C, Jiang W, Wang Q, Tan L. Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis. Transl Lung Cancer Res 2020;9:1302-23. [PMID: 32953506 DOI: 10.21037/tlcr-20-192] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
87 Andrews LP, Somasundaram A, Moskovitz JM, Szymczak-Workman AL, Liu C, Cillo AR, Lin H, Normolle DP, Moynihan KD, Taniuchi I, Irvine DJ, Kirkwood JM, Lipson EJ, Ferris RL, Bruno TC, Workman CJ, Vignali DAA. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Sci Immunol 2020;5:eabc2728. [PMID: 32680952 DOI: 10.1126/sciimmunol.abc2728] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
88 Zhao B, Zhao H, Zhao J. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med Oncol 2020;12:1758835920937612. [PMID: 32728392 DOI: 10.1177/1758835920937612] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
89 Zhou H, Sun Y, Xiu W, Han J, Zhong L, Suo J, Wei H, Wang Y, Zhu J. Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer. J Cancer Res Clin Oncol. 2020;146:2979-2988. [PMID: 32518972 DOI: 10.1007/s00432-020-03282-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
90 Jin R, Zhao J, Xia L, Li Q, Li W, Peng L, Xia Y. Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench. Ther Adv Med Oncol 2020;12:1758835920930333. [PMID: 32565926 DOI: 10.1177/1758835920930333] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
91 van Tilburg CM, Witt R, Heiss M, Pajtler KW, Plass C, Poschke I, Platten M, Harting I, Sedlaczek O, Freitag A, Meyrath D, Taylor L, Balasubramanian GP, Jäger N, Pfaff E, Jones BC, Milde T, Pfister SM, Jones DTW, Kopp-Schneider A, Witt O. INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. BMC Cancer 2020;20:523. [PMID: 32503469 DOI: 10.1186/s12885-020-07008-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
92 Xue L, Bi G, Zhan C, Zhang Y, Yuan Y, Fan H. Development and Validation of a 12-Gene Immune Relevant Prognostic Signature for Lung Adenocarcinoma Through Machine Learning Strategies. Front Oncol 2020;10:835. [PMID: 32537435 DOI: 10.3389/fonc.2020.00835] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
93 Takimoto Sato M, Ikezawa Y, Sato M, Suzuki A, Kawai Y. Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report. Mol Clin Oncol 2020;13:43-7. [PMID: 32499913 DOI: 10.3892/mco.2020.2045] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
94 Koh YW, Han JH, Haam S, Lee HW. HIP1R Expression and Its Association with PD-1 Pathway Blockade Response in Refractory Advanced NonSmall Cell Lung Cancer: A Gene Set Enrichment Analysis. J Clin Med 2020;9:E1425. [PMID: 32403421 DOI: 10.3390/jcm9051425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
95 Wang S, Zhang J, Meng FJ, Yan YJ, Wang B, Guan ZY. Combination of pembrolizumab and 125I attenuates the aggressiveness of non-small cell lung cancer. Oncol Lett 2020;19:4142-50. [PMID: 32382353 DOI: 10.3892/ol.2020.11508] [Reference Citation Analysis]
96 Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. Semin Immunol 2019;42:101305. [PMID: 31604537 DOI: 10.1016/j.smim.2019.101305] [Cited by in Crossref: 95] [Cited by in F6Publishing: 102] [Article Influence: 31.7] [Reference Citation Analysis]
97 Burgess TL, Amason JD, Rubin JS, Duveau DY, Lamy L, Roberts DD, Farrell CL, Inglese J, Thomas CJ, Miller TW. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology. PLoS One 2020;15:e0226661. [PMID: 32240171 DOI: 10.1371/journal.pone.0226661] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
98 Meyers DE, Banerji S. Biomarkers of immune checkpoint inhibitor efficacy in cancer. Curr Oncol 2020;27:S106-14. [PMID: 32368180 DOI: 10.3747/co.27.5549] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
99 Liang H, Xu Y, Chen M, Zhong W, Wang M, Zhao J. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. Thorac Cancer 2020;11:1068-75. [PMID: 32129934 DOI: 10.1111/1759-7714.13367] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
100 Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, Leroy K, Boudou-Rouquette P, Tlemsani C, Khoudour N, Arrondeau J, Thomas-Schoemann A, Blons H, Mansuet-Lupo A, Damotte D, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. Cancers (Basel) 2020;12:E473. [PMID: 32085544 DOI: 10.3390/cancers12020473] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 13.3] [Reference Citation Analysis]
101 Aslan K, Turco V, Blobner J, Sonner JK, Liuzzi AR, Núñez NG, De Feo D, Kickingereder P, Fischer M, Green E, Sadik A, Friedrich M, Sanghvi K, Kilian M, Cichon F, Wolf L, Jähne K, von Landenberg A, Bunse L, Sahm F, Schrimpf D, Meyer J, Alexander A, Brugnara G, Röth R, Pfleiderer K, Niesler B, von Deimling A, Opitz C, Breckwoldt MO, Heiland S, Bendszus M, Wick W, Becher B, Platten M. Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. Nat Commun 2020;11:931. [PMID: 32071302 DOI: 10.1038/s41467-020-14642-0] [Cited by in Crossref: 73] [Cited by in F6Publishing: 76] [Article Influence: 24.3] [Reference Citation Analysis]
102 Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol 2019;5:1008-19. [PMID: 31021376 DOI: 10.1001/jamaoncol.2019.0393] [Cited by in Crossref: 321] [Cited by in F6Publishing: 351] [Article Influence: 107.0] [Reference Citation Analysis]
103 Nayyar N, White MD, Gill CM, Lastrapes M, Bertalan M, Kaplan A, D'Andrea MR, Bihun I, Kaneb A, Dietrich J, Ferry JA, Martinez-Lage M, Giobbie-Hurder A, Borger DR, Rodriguez FJ, Frosch MP, Batchelor E, Hoang K, Kuter B, Fortin S, Holdhoff M, Cahill DP, Carter S, Brastianos PK, Batchelor TT. MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Adv 2019;3:375-83. [PMID: 30723112 DOI: 10.1182/bloodadvances.2018027672] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 14.0] [Reference Citation Analysis]
104 Villanueva F, Yuan C, Drane W, Dang L, Nguyen TC. Cancer Treatment Response to Checkpoint Inhibitors Is Associated with Cytomegalovirus Infection. Cureus 2020;12:e6670. [PMID: 32104613 DOI: 10.7759/cureus.6670] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
105 Hou Q, Xu H. Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. Adv Exp Med Biol 2020;1248:143-66. [PMID: 32185710 DOI: 10.1007/978-981-15-3266-5_7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
106 Harsini S, Rezaei N. Cancer Imaging with Radiolabeled Monoclonal Antibodies. Cancer Immunology 2020. [DOI: 10.1007/978-3-030-30845-2_32] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
107 Goto H, Sugita K, Yamamoto O. Expression of Programmed Death-Ligand 1 in Cutaneous Squamous Cell Carcinoma Arising in Sun-Exposed and Nonsun-Exposed Skin. Indian J Dermatol 2020;65:506-9. [PMID: 33487707 DOI: 10.4103/ijd.IJD_187_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
108 Wang E, Young RJ, Bhatia A. Immunotherapy and Gliomas. Glioma Imaging 2020. [DOI: 10.1007/978-3-030-27359-0_16] [Reference Citation Analysis]
109 Tessari A, Soliman SHA, Orlacchio A, Capece M, Amann JM, Visone R, Carbone DP, Palmieri D, Coppola V. RANBP9 as potential therapeutic target in non-small cell lung cancer. J Cancer Metastasis Treat 2020;6:18. [PMID: 34778565 DOI: 10.20517/2394-4722.2020.32] [Reference Citation Analysis]
110 Burgess TL, Amason JD, Rubin JS, Duveau DY, Lamy L, Roberts DD, Farrell CL, Inglese J, Thomas CJ, Miller TW. A Homogeneous SIRPα-CD47 Cell-Based, Ligand-Binding Assay: Utility for Small Molecule Drug Development in Immuno-oncology.. [DOI: 10.1101/866145] [Reference Citation Analysis]
111 Schabath MB, Dalvi TB, Dai HA, Crim AL, Midha A, Shire N, Gimbrone NT, Walker J, Greenawalt DM, Lawrence D, Rigas JR, Brody R, Potter D, Kumar NS, Huntsman SA, Gray JE. A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer. Cancer Manag Res 2019;11:9469-81. [PMID: 31819612 DOI: 10.2147/CMAR.S218635] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 Chang S, Park HK, Choi YL, Jang SJ. Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists. J Pathol Transl Med 2019;53:347-53. [PMID: 31656061 DOI: 10.4132/jptm.2019.09.29] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
113 Krekorian M, Fruhwirth GO, Srinivas M, Figdor CG, Heskamp S, Witney TH, Aarntzen EHJG. Imaging of T-cells and their responses during anti-cancer immunotherapy. Theranostics 2019;9:7924-47. [PMID: 31656546 DOI: 10.7150/thno.37924] [Cited by in Crossref: 55] [Cited by in F6Publishing: 58] [Article Influence: 13.8] [Reference Citation Analysis]
114 Duitman J, van den Ende T, Spek CA. Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis? J Clin Med 2019;8:E1547. [PMID: 31561518 DOI: 10.3390/jcm8101547] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
115 Abolarinwa BA, Ibrahim RB, Huang YH. Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer. Int J Mol Sci 2019;20:E4624. [PMID: 31540435 DOI: 10.3390/ijms20184624] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
116 Ritchie G, Gasper H, Man J, Lord S, Marschner I, Friedlander M, Lee CK. Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis. JAMA Oncol 2018;4:522-8. [PMID: 29470579 DOI: 10.1001/jamaoncol.2017.5236] [Cited by in Crossref: 53] [Cited by in F6Publishing: 61] [Article Influence: 13.3] [Reference Citation Analysis]
117 Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4:173-182. [PMID: 28973656 DOI: 10.1001/jamaoncol.2017.3064] [Cited by in Crossref: 493] [Cited by in F6Publishing: 533] [Article Influence: 123.3] [Reference Citation Analysis]
118 Low JL, Walsh RJ, Ang Y, Chan G, Soo RA. The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer. Ther Adv Med Oncol 2019;11:1758835919870360. [PMID: 31497071 DOI: 10.1177/1758835919870360] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
119 Wang J, Wu P. Correlation analysis of mRNA expression and prognosis of hOGG1 gene polymorphism in patients with non-small cell lung cancer. Oncol Lett 2019;18:2310-5. [PMID: 31402936 DOI: 10.3892/ol.2019.10586] [Reference Citation Analysis]
120 Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). J Thorac Oncol 2019;14:1853-9. [PMID: 31302234 DOI: 10.1016/j.jtho.2019.06.027] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 9.5] [Reference Citation Analysis]
121 Miller TW, Amason JD, Garcin ED, Lamy L, Dranchak PK, Macarthur R, Braisted J, Rubin JS, Burgess TL, Farrell CL, Roberts DD, Inglese J. Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors. PLoS One 2019;14:e0218897. [PMID: 31276567 DOI: 10.1371/journal.pone.0218897] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
122 Cao L, Che X, Qiu X, Li Z, Yang B, Wang S, Hou K, Fan Y, Qu X, Liu Y. M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer. Cancer Manag Res 2019;11:6125-38. [PMID: 31308749 DOI: 10.2147/CMAR.S199832] [Cited by in Crossref: 51] [Cited by in F6Publishing: 56] [Article Influence: 12.8] [Reference Citation Analysis]
123 Zang YS, Dai C, Xu X, Cai X, Wang G, Wei J, Wu A, Sun W, Jiao S, Xu Q. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. Cancer Med 2019;8:4699-708. [PMID: 31270941 DOI: 10.1002/cam4.2381] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 8.8] [Reference Citation Analysis]
124 Leclerc M, Mezquita L, Guillebot De Nerville G, Tihy I, Malenica I, Chouaib S, Mami-Chouaib F. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing. Front Immunol 2019;10:1505. [PMID: 31333652 DOI: 10.3389/fimmu.2019.01505] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
125 Alsuwaigh R, Lee J, Chan G, Chee CE, Choo SP. Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series. J Immunother Cancer 2019;7:162. [PMID: 31248458 DOI: 10.1186/s40425-019-0637-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
126 Berghoff AS, Bellosillo B, Caux C, de Langen A, Mazieres J, Normanno N, Preusser M, Provencio M, Rojo F, Wolf J, Zielinski CC. Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. ESMO Open 2019;4:e000498. [PMID: 31297240 DOI: 10.1136/esmoopen-2019-000498] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
127 Koh YW, Han JH, Haam S, Jung J, Lee HW. Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients. Oncoimmunology 2019;8:e1629261. [PMID: 31646074 DOI: 10.1080/2162402X.2019.1629261] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
128 Sun X, Roudi R, Dai T, Chen S, Fan B, Li H, Zhou Y, Zhou M, Zhu B, Yin C, Li B, Li X. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis. BMC Cancer 2019;19:558. [PMID: 31182061 DOI: 10.1186/s12885-019-5701-6] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 17.8] [Reference Citation Analysis]
129 George J, Bajaj D, Sankaramangalam K, Yoo JW, Joshi NS, Gettinger S, Price C, Farrell JJ. Incidence of pancreatitis with the use of immune checkpoint inhibitors (ICI) in advanced cancers: A systematic review and meta-analysis. Pancreatology 2019;19:587-94. [PMID: 31076344 DOI: 10.1016/j.pan.2019.04.015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
130 Remon J, Esteller L, Taus Á. Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date. Cancer Manag Res 2019;11:4893-904. [PMID: 31213908 DOI: 10.2147/CMAR.S164935] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
131 Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133-150. [PMID: 30755690 DOI: 10.1038/s41568-019-0116-x] [Cited by in Crossref: 1098] [Cited by in F6Publishing: 1175] [Article Influence: 274.5] [Reference Citation Analysis]
132 Schulze AB, Evers G, Kerkhoff A, Mohr M, Schliemann C, Berdel WE, Schmidt LH. Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. Cancers (Basel) 2019;11:E690. [PMID: 31108964 DOI: 10.3390/cancers11050690] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 9.5] [Reference Citation Analysis]
133 Cai LL, Wang J. Liquid biopsy for lung cancer immunotherapy. Oncol Lett 2019;17:4751-60. [PMID: 31186680 DOI: 10.3892/ol.2019.10166] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
134 Fruhwirth GO, Kneilling M, de Vries IJM, Weigelin B, Srinivas M, Aarntzen EHJG. The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies. Mol Imaging Biol 2018;20:696-704. [PMID: 30030697 DOI: 10.1007/s11307-018-1254-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
135 Iwahori K, Shintani Y, Funaki S, Yamamoto Y, Matsumoto M, Yoshida T, Morimoto-Okazawa A, Kawashima A, Sato E, Gottschalk S, Okumura M, Kumanogoh A, Wada H. Peripheral T cell cytotoxicity predicts T cell function in the tumor microenvironment. Sci Rep 2019;9:2636. [PMID: 30796310 DOI: 10.1038/s41598-019-39345-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
136 Ferrara R, Imbimbo M, Paget-bailly S, Malouf R, Calais F, Agazzi GM, Marchal C, Westeel V. Single or combined immune checkpoint inhibitors compared to first-line chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Cochrane Database of Systematic Reviews 2019. [DOI: 10.1002/14651858.cd013257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
137 Murthy P, Ekeke CN, Russell KL, Butler SC, Wang Y, Luketich JD, Soloff AC, Dhupar R, Lotze MT. Making cold malignant pleural effusions hot: driving novel immunotherapies. Oncoimmunology 2019;8:e1554969. [PMID: 30906651 DOI: 10.1080/2162402X.2018.1554969] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
138 Minamimoto R, Takeda Y, Hotta M, Toyohara J, Nakajima K, Naka G, Sugiyama H. 18F-FDG and 11C-4DST PET/CT for evaluating response to platinum-based doublet chemotherapy in advanced non-small cell lung cancer: a prospective study. EJNMMI Res 2019;9:4. [PMID: 30649637 DOI: 10.1186/s13550-019-0472-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
139 D'Arcangelo M, D'Incecco A, Ligorio C, Damiani S, Puccetti M, Bravaccini S, Terracciano L, Bennati C, Minuti G, Vecchiarelli S, Landi L, Milesi M, Meroni A, Ravaioli S, Tumedei MM, Incarbone M, Cappuzzo F. Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer. Oncotarget 2019;10:561-72. [PMID: 30728907 DOI: 10.18632/oncotarget.26529] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
140 Hui R, Millward M. Treatment of Pulmonary Adenocarcinoma With Immune Checkpoint Inhibitors. Pulmonary Adenocarcinoma: Approaches to Treatment 2019. [DOI: 10.1016/b978-0-323-55433-6.00010-9] [Reference Citation Analysis]
141 Lu X, Shen X. Advances in Research on Immunological Checkpoint Inhibitors in Immunotherapy of Liver Cancer. IJCM 2019;10:62-69. [DOI: 10.4236/ijcm.2019.102006] [Reference Citation Analysis]
142 Koczywas M, Amanam I. Novel Therapies for Small Cell Lung Cancer. Targeted Therapies for Lung Cancer 2019. [DOI: 10.1007/978-3-030-17832-1_8] [Reference Citation Analysis]
143 Bahman F, Elkaissi S, Greish K, Taurin S. Polymeric Micelles in Management of Lung Cancer. Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer 2019. [DOI: 10.1016/b978-0-12-815720-6.00008-3] [Reference Citation Analysis]
144 Andrews SC, Davies M. The Impact and Toxicity of Checkpoint Inhibitors in Management of Lung Cancer. Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners 2019. [DOI: 10.1007/978-3-030-16550-5_7] [Reference Citation Analysis]
145 Zhou Y, Chen C, Zhang X, Fu S, Xue C, Ma Y, Fang W, Yang Y, Hou X, Huang Y, Zhao H, Hong S, Zhang L. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis. J Immunother Cancer 2018;6:155. [PMID: 30577837 DOI: 10.1186/s40425-018-0477-9] [Cited by in Crossref: 56] [Cited by in F6Publishing: 64] [Article Influence: 11.2] [Reference Citation Analysis]
146 Jia Q, Wu W, Wang Y, Alexander PB, Sun C, Gong Z, Cheng JN, Sun H, Guan Y, Xia X, Yang L, Yi X, Wan YY, Wang H, He J, Futreal PA, Li QJ, Zhu B. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun 2018;9:5361. [PMID: 30560866 DOI: 10.1038/s41467-018-07767-w] [Cited by in Crossref: 180] [Cited by in F6Publishing: 196] [Article Influence: 36.0] [Reference Citation Analysis]
147 Ancevski Hunter K, Socinski MA, Villaruz LC. PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 2018;22:1-10. [PMID: 29119407 DOI: 10.1007/s40291-017-0308-6] [Cited by in Crossref: 102] [Cited by in F6Publishing: 110] [Article Influence: 20.4] [Reference Citation Analysis]
148 Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH, Sautès-Fridman C. The clinical role of the TME in solid cancer. Br J Cancer 2019;120:45-53. [PMID: 30413828 DOI: 10.1038/s41416-018-0327-z] [Cited by in Crossref: 185] [Cited by in F6Publishing: 201] [Article Influence: 37.0] [Reference Citation Analysis]
149 Hernandez-Martinez JM, Zatarain-Barrón ZL, Cardona AF, Arrieta O. The importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy. J Thorac Dis 2018;10:S4096-100. [PMID: 30631565 DOI: 10.21037/jtd.2018.10.24] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
150 Schmidt EV. Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer. Semin Immunopathol 2019;41:21-30. [PMID: 30374524 DOI: 10.1007/s00281-018-0714-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 8.0] [Reference Citation Analysis]
151 Tachihara M, Negoro S, Inoue T, Tamiya M, Akazawa Y, Uenami T, Urata Y, Hattori Y, Hata A, Katakami N, Yokota S. Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316). BMC Cancer 2018;18:946. [PMID: 30285770 DOI: 10.1186/s12885-018-4819-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
152 Yan X, Zhang S, Deng Y, Wang P, Hou Q, Xu H. Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. Front Pharmacol 2018;9:1050. [PMID: 30294272 DOI: 10.3389/fphar.2018.01050] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 7.6] [Reference Citation Analysis]
153 Zhang J, Medeiros LJ, Young KH. Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Front Oncol 2018;8:351. [PMID: 30250823 DOI: 10.3389/fonc.2018.00351] [Cited by in Crossref: 53] [Cited by in F6Publishing: 60] [Article Influence: 10.6] [Reference Citation Analysis]
154 Liede A, Hernandez RK, Wade SW, Bo R, Nussbaum NC, Ahern E, Dougall WC, Smyth MJ. An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. Oncoimmunology 2018;7:e1480301. [PMID: 30524886 DOI: 10.1080/2162402X.2018.1480301] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 7.6] [Reference Citation Analysis]
155 Kanwal B, Biswas S, Seminara RS, Jeet C. Immunotherapy in Advanced Non-small Cell Lung Cancer Patients: Ushering Chemotherapy Through the Checkpoint Inhibitors? Cureus 2018;10:e3254. [PMID: 30416904 DOI: 10.7759/cureus.3254] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
156 Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, Signoretti S, Sholl LM, Engelman JA, Getz G, Jänne PA, Haddad RI, Choueiri TK, Barbie DA, Haq R, Awad MM, Schadendorf D, Hodi FS, Bellmunt J, Wong KK, Hammerman P, Van Allen EM. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet 2018;50:1271-81. [PMID: 30150660 DOI: 10.1038/s41588-018-0200-2] [Cited by in Crossref: 284] [Cited by in F6Publishing: 303] [Article Influence: 56.8] [Reference Citation Analysis]
157 O'Beirn M, Benghiat H, Meade S, Heyes G, Sawlani V, Kong A, Hartley A, Sanghera P. The Expanding Role of Radiosurgery for Brain Metastases. Medicines (Basel) 2018;5:E90. [PMID: 30110927 DOI: 10.3390/medicines5030090] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
158 Meyers DE, Bryan PM, Banerji S, Morris DG. Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer. Curr Oncol 2018;25:e324-34. [PMID: 30111979 DOI: 10.3747/co.25.3976] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
159 Jiao S, Zang Y, Dai C, Xu X, Cai X, Wang G, Wei J, Wu A, Sun W, Xu Q. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1,000 Chinese patients with cancer.. [DOI: 10.1101/366062] [Reference Citation Analysis]
160 Li B, Huang X, Fu L. Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis. Onco Targets Ther 2018;11:3691-6. [PMID: 29983577 DOI: 10.2147/OTT.S156421] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
161 Siu LL, Ivy SP, Dixon EL, Gravell AE, Reeves SA, Rosner GL. Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. Clin Cancer Res 2017;23:4950-8. [PMID: 28864723 DOI: 10.1158/1078-0432.CCR-16-3079] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 6.6] [Reference Citation Analysis]
162 Sui JD, Wang Y, Wan Y, Wu YZ. Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies. Drug Des Devel Ther 2018;12:1645-57. [PMID: 29922039 DOI: 10.2147/DDDT.S167077] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
163 Wu YL, Wang CL, Liao ML, Guan ZZ, Gao CY, Lu S, Zhao MF, Wang J, Liu XQ, Yang JJ, Liang J, Mao WM, Han BH, Zhang XC, Song Y, Feng JF, Ma SL, Wu G, Zhou CC, Chen KN, Cheng Y, He Y, Chen C, Wang Q, Lin JZ, Zhu B, Liu YP, Hu Y, Qiao GB, Zhou Q, Song QB, Wu N, Wu L, Huang C, Fu XL, Xiong JP, Hu J, Hu CP, Chang JH, Zhao Q, Zhao J, Zhou PH, Ma ZY, Chen Y, Zhang HL, Yang F, Wang JJ, Pan YY, Yang XN, Fan Y, Liu Z, Fan W, Yang N, Guan YF, Sun H, Zhong WZ. A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. Transl Lung Cancer Res 2018;7:428-36. [PMID: 30050780 DOI: 10.21037/tlcr.2018.04.15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
164 Ferrara R, Pilotto S, Caccese M, Grizzi G, Sperduti I, Giannarelli D, Milella M, Besse B, Tortora G, Bria E. Do immune checkpoint inhibitors need new studies methodology? J Thorac Dis 2018;10:S1564-80. [PMID: 29951307 DOI: 10.21037/jtd.2018.01.131] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 7.2] [Reference Citation Analysis]
165 Jaafar J, Fernandez E, Alwan H, Philippe J. Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. Endocr Connect 2018;7:R196-211. [PMID: 29739808 DOI: 10.1530/EC-18-0079] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
166 Peng L, Wu YL. Immunotherapy in the Asiatic population: any differences from Caucasian population? J Thorac Dis 2018;10:S1482-93. [PMID: 29951300 DOI: 10.21037/jtd.2018.05.106] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
167 Xue S, Hu M, Li P, Ma J, Xie L, Teng F, Zhu Y, Fan B, Mu D, Yu J. Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma. Oncotarget 2017;8:49702-12. [PMID: 28591697 DOI: 10.18632/oncotarget.17922] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 10.8] [Reference Citation Analysis]
168 Lin SY, Yang CY, Liao BC, Ho CC, Liao WY, Chen KY, Tsai TH, Hsu CL, Hsu WH, Su KY, Chang YL, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. J Cancer 2018;9:1813-20. [PMID: 29805708 DOI: 10.7150/jca.24985] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
169 Liu L, Ruiz J, O'Neill SS, Grant SC, Petty WJ, Yang M, Chen K, Topaloglu U, Pasche B, Zhang W. Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1. Mol Cancer 2018;17:81. [PMID: 29650000 DOI: 10.1186/s12943-018-0832-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
170 Langhammer S, Scheerer J. Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. Oncotarget 2017;8:43555-70. [PMID: 28402937 DOI: 10.18632/oncotarget.16674] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
171 Shah UA, Nandikolla AG, Rajdev L. Immunotherapeutic Approaches to Biliary Cancer. Curr Treat Options Oncol 2017;18:44. [PMID: 28660602 DOI: 10.1007/s11864-017-0486-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
172 Zhao B, Zhang W, Yu D, Xu J, Wei Y. The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials. Cancer Med 2018;7:1642-59. [PMID: 29573217 DOI: 10.1002/cam4.1387] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
173 Mohamad O, Diaz de Leon A, Schroeder S, Leiker A, Christie A, Zhang-Velten E, Trivedi L, Khan S, Desai NB, Laine A, Albuquerque K, Iyengar P, Arriaga Y, Courtney K, Gerber DE, Hammers H, Choy H, Timmerman R, Brugarolas J, Hannan R. Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. Oncoimmunology 2018;7:e1440168. [PMID: 29900043 DOI: 10.1080/2162402X.2018.1440168] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
174 Li P, Liu HL, Zhang ZQ, Lv XD, Chang YX, Wang HJ, Ma J, Ma ZY, Qu XJ, Teng YE. Single nucleotide polymorphisms of casitas B-lineage lymphoma proto-oncogene-b predict outcomes of patients with advanced non-small cell lung cancer after first-line platinum based doublet chemotherapy. J Thorac Dis 2018;10:1635-47. [PMID: 29707316 DOI: 10.21037/jtd.2018.02.31] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
175 Guirgis HM. The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective. J Immunother Cancer 2018;6:15. [PMID: 29463302 DOI: 10.1186/s40425-018-0320-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
176 Botticelli A, Zizzari I, Mazzuca F, Ascierto PA, Putignani L, Marchetti L, Napoletano C, Nuti M, Marchetti P. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment. Oncotarget 2017;8:8890-9. [PMID: 27806346 DOI: 10.18632/oncotarget.12985] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
177 Dhar M, Wong J, Che J, Matsumoto M, Grogan T, Elashoff D, Garon EB, Goldman JW, Sollier Christen E, Di Carlo D, Kulkarni RP. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. Sci Rep 2018;8:2592. [PMID: 29416054 DOI: 10.1038/s41598-018-19245-w] [Cited by in Crossref: 53] [Cited by in F6Publishing: 62] [Article Influence: 10.6] [Reference Citation Analysis]
178 Niyongere S, Saltos A, Gray JE. Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. J Thorac Dis 2018;10:S433-50. [PMID: 29593889 DOI: 10.21037/jtd.2017.12.120] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
179 Ernani V, Ganti AK. Immunotherapy in treatment naïve advanced non-small cell lung cancer. J Thorac Dis 2018;10:S412-21. [PMID: 29593887 DOI: 10.21037/jtd.2017.12.94] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
180 Sau S, Alsaab HO, Bhise K, Alzhrani R, Nabil G, Iyer AK. Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment. J Control Release 2018;274:24-34. [PMID: 29391232 DOI: 10.1016/j.jconrel.2018.01.028] [Cited by in Crossref: 88] [Cited by in F6Publishing: 83] [Article Influence: 17.6] [Reference Citation Analysis]
181 Li P, Liu H, Zhang Z, Lv X, Wang H, Ma J, Ma Z, Qu X, Teng YE. Expression and Comparison of Cbl-b in Lung Squamous Cell Carcinoma and Adenocarcinoma. Med Sci Monit 2018;24:623-35. [PMID: 29384143 DOI: 10.12659/msm.908076] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
182 Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis 2018;9:117. [PMID: 29371589 DOI: 10.1038/s41419-017-0063-y] [Cited by in Crossref: 227] [Cited by in F6Publishing: 248] [Article Influence: 45.4] [Reference Citation Analysis]
183 Abdin SM, Zaher DM, Arafa EA, Omar HA. Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. Cancers (Basel). 2018;10. [PMID: 29370105 DOI: 10.3390/cancers10020032] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 7.8] [Reference Citation Analysis]
184 Filosso PL, Guerrera F, Lausi PO, Ruffini E. Locally advanced non-small cell lung cancer treatment: another step forward. J Thorac Dis 2017;9:4908-11. [PMID: 29312689 DOI: 10.21037/jtd.2017.11.103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
185 Goss G, Mok T. Systemic Options for Second-Line Therapy and Beyond. IASLC Thoracic Oncology 2018. [DOI: 10.1016/b978-0-323-52357-8.00045-7] [Reference Citation Analysis]
186 Hirata K, Orita M, Kawamura D, Hoshii Y. Perforative Peritonitis of the Ileum during Lung Cancer Treatment with Nivolumab. Jpn J Gastroenterol Surg, Nihon Shokaki Geka Gakkai zasshi 2018;51:279-285. [DOI: 10.5833/jjgs.2017.0100] [Reference Citation Analysis]
187 Cui S, Dong L, Qian J, Ye L, Jiang L. Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells. J Cancer 2018;9:129-34. [PMID: 29290777 DOI: 10.7150/jca.21842] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
188 Morgensztern D, Herbst RS. Immune Checkpoint Inhibition in Lung Cancer. Oncoimmunology 2018. [DOI: 10.1007/978-3-319-62431-0_20] [Reference Citation Analysis]
189 Saito M, Saito K, Shiraishi K, Maeda D, Suzuki H, Minamiya Y, Kono K, Kohno T, Goto A. Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. Mol Clin Oncol 2018;8:310-4. [PMID: 29435295 DOI: 10.3892/mco.2017.1536] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 0.3] [Reference Citation Analysis]
190 Xu-Monette ZY, Zhang M, Li J, Young KH. PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? Front Immunol. 2017;8:1597. [PMID: 29255458 DOI: 10.3389/fimmu.2017.01597] [Cited by in Crossref: 152] [Cited by in F6Publishing: 160] [Article Influence: 25.3] [Reference Citation Analysis]
191 Hu YB, Zhang Q, Li HJ, Michot JM, Liu HB, Zhan P, Lv TF, Song Y; written on behalf of the AME Academic Lung Cancer Cooperation Group. Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res 2017;6:S8-S20. [PMID: 29299404 DOI: 10.21037/tlcr.2017.12.10] [Cited by in Crossref: 66] [Cited by in F6Publishing: 74] [Article Influence: 11.0] [Reference Citation Analysis]
192 Arrieta O, Montes-Servín E, Hernandez-Martinez JM, Cardona AF, Casas-Ruiz E, Crispín JC, Motola D, Flores-Estrada D, Barrera L. Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. Oncotarget 2017;8:101994-2005. [PMID: 29254220 DOI: 10.18632/oncotarget.22025] [Cited by in Crossref: 54] [Cited by in F6Publishing: 63] [Article Influence: 9.0] [Reference Citation Analysis]
193 Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, Liu N, Yan CX. Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Front Pharmacol. 2017;8:730. [PMID: 29093678 DOI: 10.3389/fphar.2017.00730] [Cited by in Crossref: 231] [Cited by in F6Publishing: 249] [Article Influence: 38.5] [Reference Citation Analysis]
194 Oda SK, Daman AW, Garcia NM, Wagener F, Schmitt TM, Tan X, Chapuis AG, Greenberg PD. A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia. Blood 2017;130:2410-9. [PMID: 29042364 DOI: 10.1182/blood-2017-04-777052] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
195 Jin Y, Jiang Q, Xin T. Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab. Thorac Cancer 2018;9:164-6. [PMID: 29027754 DOI: 10.1111/1759-7714.12522] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
196 Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP, Khuri FR, Ahmed R, Ramalingam SS. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Cancer. 2018;124:271-277. [PMID: 28960263 DOI: 10.1002/cncr.31043] [Cited by in Crossref: 169] [Cited by in F6Publishing: 196] [Article Influence: 28.2] [Reference Citation Analysis]
197 Pérol M, Paulus V, Swalduz A, Avrillon V. Traitement de première ligne et de maintenance dans les CBNPC avancés en l’absence d’addiction oncogénique. Revue des Maladies Respiratoires Actualités 2017;9:234-247. [DOI: 10.1016/s1877-1203(17)30056-3] [Reference Citation Analysis]
198 Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J, Spisek R, Demaria S, Formenti SC, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immune checkpoint blockers for cancer therapy. Oncoimmunology 2017;6:e1373237. [PMID: 29147629 DOI: 10.1080/2162402X.2017.1373237] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 8.2] [Reference Citation Analysis]
199 Greystoke A, Steele N, Arkenau HT, Blackhall F, Md Haris N, Lindsay CR, Califano R, Voskoboynik M, Summers Y, So K, Ghiorghiu D, Dymond AW, Hossack S, Plummer R, Dean E. SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. Br J Cancer 2017;117:938-46. [PMID: 28950288 DOI: 10.1038/bjc.2017.271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
200 Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwecki B, Liu H, Kokolus KM, Eng JW, Messmer MN, Attwood K, Abrams SI, Hylander BL, Repasky EA. β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy. Cancer Res 2017;77:5639-51. [PMID: 28819022 DOI: 10.1158/0008-5472.CAN-17-0546] [Cited by in Crossref: 109] [Cited by in F6Publishing: 119] [Article Influence: 18.2] [Reference Citation Analysis]
201 Tibaldi C, Lunghi A, Baldini E. Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. World J Clin Oncol 2017; 8(4): 320-328 [PMID: 28848698 DOI: 10.5306/wjco.v8.i4.320] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
202 Dwary AD, Master S, Patel A, Cole C, Mansour R, Mills G, Koshy N, Peddi P, Burton G, Hammoud D, Beedupalli K. Excellent response to chemotherapy post immunotherapy. Oncotarget 2017;8:91795-802. [PMID: 29207685 DOI: 10.18632/oncotarget.20030] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
203 Illouz F, Briet C, Cloix L, Le Corre Y, Baize N, Urban T, Martin L, Rodien P. Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists. Cancer Med 2017;6:1923-9. [PMID: 28719055 DOI: 10.1002/cam4.1145] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
204 Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev 2017;276:80-96. [PMID: 28258692 DOI: 10.1111/imr.12519] [Cited by in Crossref: 433] [Cited by in F6Publishing: 465] [Article Influence: 72.2] [Reference Citation Analysis]
205 Wang DY, Ye F, Zhao S, Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. Oncoimmunology 2017;6:e1344805. [PMID: 29123955 DOI: 10.1080/2162402X.2017.1344805] [Cited by in Crossref: 99] [Cited by in F6Publishing: 92] [Article Influence: 16.5] [Reference Citation Analysis]
206 Park JA, Cheung NV. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. Cancer Treat Rev 2017;58:22-33. [PMID: 28622628 DOI: 10.1016/j.ctrv.2017.05.006] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 10.0] [Reference Citation Analysis]
207 Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017;376:2415-2426. [PMID: 28636851 DOI: 10.1056/nejmoa1613493] [Cited by in Crossref: 1476] [Cited by in F6Publishing: 1688] [Article Influence: 246.0] [Reference Citation Analysis]
208 Wang H, Yu X, Fan Y. [Prospect and Current Situation of Immune Checkpoint Inhibitors 
in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients]. Zhongguo Fei Ai Za Zhi 2017;20:427-32. [PMID: 28641702 DOI: 10.3779/j.issn.1009-3419.2017.06.10] [Reference Citation Analysis]
209 Chae YK, Wang S, Nimeiri H, Kalyan A, Giles FJ. Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review. Oncotarget. 2017;8:57889-57897. [PMID: 28915720 DOI: 10.18632/oncotarget.18361] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
210 Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, Gandhi L, Eder JP, Ahn MJ, Horn L. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017;28:874-881. [PMID: 28168303 DOI: 10.1093/annonc/mdx008] [Cited by in Crossref: 149] [Cited by in F6Publishing: 162] [Article Influence: 24.8] [Reference Citation Analysis]
211 Fang X, Xiu B, Yang Z, Qiu W, Zhang L, Zhang S, Wu Y, Zhu X, Chen X, Xie S, Yi X, Liang A, Zeng Y. The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma. Medicine (Baltimore) 2017;96:e6398. [PMID: 28403071 DOI: 10.1097/MD.0000000000006398] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
212 Eckert F, Jelas I, Oehme M, Huber SM, Sonntag K, Welker C, Gillies SD, Strittmatter W, Zips D, Handgretinger R, Schilbach K. Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo. Oncoimmunology 2017;6:e1323161. [PMID: 28680762 DOI: 10.1080/2162402X.2017.1323161] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
213 Somasundaram A, Burns TF. The next generation of immunotherapy: keeping lung cancer in check. J Hematol Oncol. 2017;10:87. [PMID: 28434399 DOI: 10.1186/s13045-017-0456-5] [Cited by in Crossref: 64] [Cited by in F6Publishing: 67] [Article Influence: 10.7] [Reference Citation Analysis]
214 Pianko MJ, Liu Y, Bagchi S, Lesokhin AM. Immune checkpoint blockade for hematologic malignancies: a review. Stem Cell Investig 2017;4:32. [PMID: 28529947 DOI: 10.21037/sci.2017.03.04] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
215 Xue S, Hu M, Iyer V, Yu J. Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.J Hematol Oncol. 2017;10:81. [PMID: 28388955 DOI: 10.1186/s13045-017-0455-6] [Cited by in Crossref: 87] [Cited by in F6Publishing: 91] [Article Influence: 14.5] [Reference Citation Analysis]
216 Kobayashi H, Omori S, Nakashima K, Wakuda K, Ono A, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi T. Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. Int J Clin Oncol 2017;22:690-7. [PMID: 28382561 DOI: 10.1007/s10147-017-1118-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
217 Kashiwada T, Saito Y, Minegishi Y, Kokuho N, Takahashi A, Takahashi S, Atsumi K, Seike M, Azuma A, Kubota K, Terasaki Y, Gemma A. Granuloma-forming interstitial pneumonia induced by nivolumab: a possible immune-related adverse event of the lung. Int Cancer Conf J 2017;6:131-4. [PMID: 31149487 DOI: 10.1007/s13691-017-0291-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
218 Sun J. PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer. Precis Future Med 2017;1:3-9. [DOI: 10.23838/pfm.2017.00066] [Reference Citation Analysis]
219 Remon J, Besse B, Soria JC. Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer? BMC Med 2017;15:55. [PMID: 28285592 DOI: 10.1186/s12916-017-0819-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 55] [Article Influence: 6.3] [Reference Citation Analysis]
220 Saito M, Suzuki H, Kono K, Takenoshita S, Kohno T. Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surg Today 2018;48:1-8. [PMID: 28280984 DOI: 10.1007/s00595-017-1497-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
221 Roussel H, De Guillebon E, Biard L, Mandavit M, Gibault L, Fabre E, Antoine M, Hofman P, Beau-Faller M, Blons H, Danel C, Barthes FLP, Gey A, Granier C, Wislez M, Laurent-Puig P, Oudard S, Bruneval P, Badoual C, Cadranel J, Tartour E. Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. Oncoimmunology 2017;6:e1286437. [PMID: 28507793 DOI: 10.1080/2162402X.2017.1286437] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
222 Jiang Z, Pan Z, Ren X. [Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2017;20:138-42. [PMID: 28228226 DOI: 10.3779/j.issn.1009-3419.2017.02.09] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
223 Wang C, Yu X, Wang W. A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer. Medicine (Baltimore) 2016;95:e5539. [PMID: 28033249 DOI: 10.1097/MD.0000000000005539] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
224 Lin JJ, Riely GJ, Shaw AT. Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov 2017;7:137-55. [PMID: 28122866 DOI: 10.1158/2159-8290.CD-16-1123] [Cited by in Crossref: 282] [Cited by in F6Publishing: 306] [Article Influence: 47.0] [Reference Citation Analysis]
225 Braschi-Amirfarzan M, Tirumani SH, Hodi FS Jr, Nishino M. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Korean J Radiol 2017;18:42-53. [PMID: 28096717 DOI: 10.3348/kjr.2017.18.1.42] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
226 Chopra M. Checkpoint inhibitors for the treatment of non-small-cell lung cancer: news from the 2016 European Society for Medical Oncology Annual Congress. Drugs Ther Perspect 2017;33:126-32. [DOI: 10.1007/s40267-016-0369-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
227 Cortinovis DL, Canova S, Abbate M, Colonese F, Bidoli P. Focus on Nivolumab in NSCLC. Front Med (Lausanne) 2016;3:67. [PMID: 28018902 DOI: 10.3389/fmed.2016.00067] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
228 Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): Results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18:31-41. [PMID: 27932067 DOI: 10.1016/s1470-2045(16)30624-6] [Cited by in Crossref: 594] [Cited by in F6Publishing: 671] [Article Influence: 84.9] [Reference Citation Analysis]
229 O'Kane GM, Leighl NB. Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. Transl Lung Cancer Res 2016;5:628-36. [PMID: 28149757 DOI: 10.21037/tlcr.2016.09.05] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
230 Bansal P, Osman D, Gan GN, Simon GR, Boumber Y. Recent Advances in Immunotherapy in Metastatic NSCLC. Front Oncol 2016;6:239. [PMID: 27896216 DOI: 10.3389/fonc.2016.00239] [Cited by in Crossref: 9] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
231 Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol 2016;17:1497-508. [PMID: 27745820 DOI: 10.1016/S1470-2045(16)30498-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
232 Hutarew G. PD-L1 testing, fit for routine evaluation? From a pathologist's point of view. Memo 2016;9:201-6. [PMID: 28058063 DOI: 10.1007/s12254-016-0292-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
233 Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L; KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:1497-1508. [PMID: 27745820 DOI: 10.1016/s1470-2045(16)30498-3] [Cited by in Crossref: 877] [Cited by in F6Publishing: 913] [Article Influence: 125.3] [Reference Citation Analysis]
234 Dempke WC, Fenchel K. Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer? Transl Lung Cancer Res 2016;5:538-42. [PMID: 27826536 DOI: 10.21037/tlcr.2016.10.01] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
235 Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French LE, Speiser DE, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology 2016;5:e1231292. [PMID: 27999741 DOI: 10.1080/2162402X.2016.1231292] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 10.3] [Reference Citation Analysis]
236 Liu SV, Giaccone G. Lung cancer: First-line immunotherapy in lung cancer - taking the first step. Nat Rev Clin Oncol 2016;13:595-6. [PMID: 27620712 DOI: 10.1038/nrclinonc.2016.148] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
237 Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016;34:2969-2979. [PMID: 27354481 DOI: 10.1200/jco.2016.66.9861] [Cited by in Crossref: 298] [Cited by in F6Publishing: 342] [Article Influence: 42.6] [Reference Citation Analysis]
238 Malhotra J, Jabbour SK, Aisner J. Current state of immunotherapy for non-small cell lung cancer. Transl Lung Cancer Res 2017;6:196-211. [PMID: 28529902 DOI: 10.21037/tlcr.2017.03.01] [Cited by in Crossref: 100] [Cited by in F6Publishing: 122] [Article Influence: 6.3] [Reference Citation Analysis]
239 Jia W, Gao Q, Han A, Zhu H, Yu J. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med. 2019;16:655-670. [PMID: 31908886 DOI: 10.20892/j.issn.2095-3941.2019.0144] [Cited by in Crossref: 17] [Cited by in F6Publishing: 42] [Reference Citation Analysis]